Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Autoimmune Diseases Model Development Service
Are you currently facing long drug development cycles and challenges in developing clinically relevant models for autoimmune and inflammatory diseases? Our NHP Autoimmune Diseases Model Development service helps you accelerate drug discovery and reduce the risk of clinical failure. Through a comprehensive, multi-species platform and high-translational non-human primate (NHP) models, we provide a sophisticated solution that bridges the gap between preclinical research and human clinical trials.
Introduction to NHP Autoimmune Diseases Model Development
What Our Service Is
Our NHP Autoimmune Diseases Model Development service provides a high-translational platform for evaluating drug candidates targeting autoimmune and inflammatory diseases (AIID). We specialize in leveraging NHP models, which possess significant biological advantages over traditional rodent models, including closer genetic and immunological similarities to humans. This makes them the ideal choice for late-stage preclinical development. Our services are essential for:
- Validating novel biologic therapies, such as monoclonal antibodies, that may not cross-react with rodent proteins.
- Evaluating the efficacy and safety of small molecule drugs in a more clinically relevant context.
- Studying complex disease pathogenesis and the long-term effects of a compound in a system more closely mimicking human physiology.
Why Choose Us?
Developing effective therapies for AIID is a complex and high-stakes endeavor. While rodent models offer a cost-effective and rapid initial screening tool, their predictive value for human diseases can be limited due to genetic and immunological differences. This is a primary reason for the high attrition rate in clinical trials. At Creative Biolabs, we believe that prioritizing clinical relevance is key to success. Our NHP models offer:
- Genetic Heterogeneity: Unlike inbred rodent strains, our NHPs exhibit natural genetic variation, which more accurately reflects the human patient population.
- Mature Immune Systems: The immune systems of NHPs are physiologically and immunologically more mature and complex, making them a superior model for studying immune-driven diseases.
- High Translational Value: Our models have been meticulously developed to provide highly reproducible and predictive data, reducing the risk of clinical failure and accelerating your path to market.
Fig.1 Proton density cerebral images of a marmoset, rat, and mouse.1
Key Benefits of Our Service
We provide a distinct advantage in preclinical drug development by offering a seamless and scientifically robust experience designed to accelerate your project.
- Responsive and Streamlined Workflow: Our processes are optimized for speed and efficiency. We offer a rapid response to inquiries and a streamlined project initiation, ensuring your study gets underway as quickly as possible.
- Unrivaled NHP Resources: With access to a vast network of NHP models, we can provide the specific species and models required to meet your study's unique needs, including validated models for rheumatoid arthritis, asthma, and inflammatory bowel diseases.
- Tailored Customization: Every project is unique. We provide a highly customized approach to model selection, study design, and data analysis, ensuring the research aligns perfectly with your scientific objectives.
- In-Depth Reporting & Analysis: Our deliverables go beyond raw data. You will receive comprehensive study reports with detailed histological analysis, biomarker profiling, and expert interpretation. We provide the full context of your data, allowing for informed decision-making.
How Creative Biolabs' NHP Model Development Can Assist Your Project?
Our NHP models provide a critical bridge from early-stage research to clinical development, offering concrete solutions and powerful data.
01
Required Starting Materials
02
Study Design & Model Selection
03
Animal Procurement & Quarantine
04
Dosing & Monitoring
05
Sample Collection & Analysis
06
Data Reporting & Consultation
Key Deliverables
- Detailed study report with comprehensive data interpretation.
- Raw data files from all experiments (e.g., PK/PD, biomarker, flow cytometry).
- Histopathology slides with model annotations and expert analysis.
- Bio-samples (upon request) for further client-side analysis.
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: Why should I use an NHP model instead of a mouse model for my project?
A: Mouse models are great for initial screening, but NHPs are superior for later-stage preclinical research. Their closer genetic and immunological relationship to humans provides more clinically relevant and predictive data, which can reduce the risk of clinical trial failure and ultimately save time and resources.
Q: Is an NHP study more expensive than a rodent study?
A: While the initial cost is higher due to the complexities of working with NHPs, the value gained is immense. The data is more translatable to humans, which can prevent costly failures in clinical trials. A successful NHP study is a wise investment that can significantly de-risk your program.
Q: How do you ensure the ethical treatment and welfare of your animals?
A: We operate under the highest ethical standards, adhering to all international guidelines for animal welfare. Our facilities are fully accredited, and all procedures are conducted by trained and experienced staff to ensure the health and well-being of our animals throughout the study.
Q: Can you create a custom NHP model for a rare disease?
A: Yes, our team has extensive experience in developing and validating novel models. If you have a specific research need for a rare disease, we would be happy to discuss a customized solution and explore the feasibility of developing a new model for your project.
Q: How do I know which NHP model is right for my drug candidate?
A: Selecting the right model is a critical step. Our scientific experts are available to provide a detailed consultation to help you choose the most appropriate model based on your drug's target, mechanism of action, and therapeutic goals.
Contact Us
Creative Biolabs' NHP Autoimmune Diseases Model Development service provides a powerful, integrated solution to the complexities of drug discovery. By leveraging the high translational value of non-human primate models and a full suite of analytical services, we help you overcome preclinical challenges, de-risk your pipeline, and accelerate your path to delivering life-changing therapies. For detailed information and to discuss your project, please contact our team of experts.
Reference
- 't Hart, Bert A. "Primate autoimmune disease models; lost for translation?" Clinical & translational immunology vol. 5,12 e122. 30 Dec. 2016. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1038/cti.2016.82